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A B S T R A C T
Objectives: To investigate the direct effects of progesterone receptor (PR) agonists on proliferation and
apoptosis of human adenomyotic cells.
Study Design: Human primary cultures of adenomyotic stromal cells (ASCs) from 24 patients with
adenomyosis were co-treated with estradiol (E2) plus the PR agonists, endogenous progesterone (P) or
the synthetic progestin dienogest (DNG), which is used to treat endometriosis. In ASCs, anti-proliferative
effects and induction of apoptosis were evaluated in the presence or absence of P (108–106M) or DNG
(108–106M) in culture medium containing E2. Cellular proliferation was analyzed with bromodeox-
yuridine incorporation and ﬂow cytometry. Apoptosis was detected with annexin V/7-amino-
actinomycin D (7-AAD) staining with ﬂow cytometry and cellular caspase 3/7 activity.
Results: P and DNG signiﬁcantly decreased the proportion of cells in the S phase. In addition, both P and
DNG increased apoptosis as measured by annexin V-positive/7-AAD -negative cells and caspase 3/7
activity.
Conclusions: Both endogenous P and synthetic progestin directly inhibited cellular proliferation and
induced apoptosis in human ASCs. These pharmacological features of progestational compounds provide
insight into the therapeutic strategy for the treatment of adenomyosis.
ã 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Introduction
Adenomyosis is characterized by the intramyometrial presence
of ectopic endometrial glandular tissue and stromal cells
surrounded by reactive, hyperplastic myometrium [1]. The details
of the pathology of adenomyosis are unclear. Adenomyosis is an
estrogen-dependent disease that involves the estrogen receptors
in adenomyotic tissue. Estrogen synthetic enzymes, such as
aromatase and estrogen sulphatase, are more highly expressed
in adenomyotic tissue than in normal endometrial tissue [2], and
thus, estrogen sensitivity is higher in adenomyotic tissue. In
addition, apoptotic cells in eutopic endometrium from adeno-
myosis patients are rare compared with endometrium from
healthy controls. Expression of the antiapoptotic factor Bcl-2 is
higher in adenomyotic tissue than in normal endometrial tissue
[3]. Adenomyotic cells may be resistant to apoptosis that is
regulated by endogenous female sex hormones. These ﬁndings
suggest that normal endometrial cells and adenomyotic cells have
different features.
The frequency of adenomyosis has been reported to be
approximately 20%–30%, and the prevalence of adenomyosis is
70% [1]. Hence, this is not a rare disease. Surgery and medical
therapies are available to treat adenomyosis [1]. The main
medications to relieve the symptoms of adenomyosis are
hormonal agents, such as synthetic P receptor (PR) agonists,
progestins including the levonorgestrel-releasing intrauterine
system (LNG-IUS), danazol, gonadotropin-releasing hormone
analogs, and oral contraceptives (OCs) [1]. However, gonadotro-
pin-releasing hormone analogs cause hypoestrogenism and induce
additional adverse effects, hot ﬂashes and bone mineral density
decline [4]. Danazol also produces changes in hypoestrogenism
and androgenic effects [5]. OCs increase the risk of venous
thromboembolism [6] and possibly increase adenomyotic volume
in some cases, because OCs include estrogen. Thus, the use of these
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agents is limited for the treatment of adenomyosis. Although only a
few reports have shown that oral progestin is effective for the
treatment of adenomyosis, an intrauterine device containing
levonorgestrel [1,4], a progestin, has shown to be highly effective
for the treatment of adenomyosis. Thus progestins seem to
improve the symptoms and progression of adenomyosis [1].
Progestins do not induce hypoestrogenism [7], and some
progestins, such as fourth-generation progestins, have no andro-
genic effects [8]. Therefore, progestins can be used for long-term
treatment with few adverse effects and seem to be a useful option
for medical treatment of adenomyosis.
One of the pharmacological effects of progestins in adeno-
myosis may be associated with anti-ovulatory activity [9].
However, local administration of progestins, such as occurs with
LNG-IUS, is highly effective for the treatment of adenomyosis [1,4]
even though LNG-IUS does not provide complete anti-ovulatory
activity [4,10]. Progestins have direct anti-proliferative and anti-
inﬂammatory effects on some kinds of cells, such as endometrial
and endometriotic cells [11–16]. However, few studies have
investigated the direct effect of progestins on adenomyotic cells.
Clarifying the direct effects of progestins on adenomyotic cells as a
treatment strategy for adenomyosis is important. In addition,
although in vitro studies using adenomyotic cells are informative,
few reports have been published using human primary cultures
isolated from adenomyotic tissue or evaluating drugs in it.
In the present study, to conﬁrm the inﬂuence of progestational
compounds in the progression of adenomyosis, we examined the
direct effects of endogenous progesterone (P) and the fourth-
generation progestin dienogest (DNG), which is a selective PR
agonist, on the proliferation and apoptosis of human primary
cultures of adenomyotic stromal cells (ASCs) in the presence of E2,
which plays a pathological role in adenomyosis.
Materials and methods
Patients and samples
Samples were collected during gynecological surgery and were
histologically conﬁrmed to include areas of adenomyosis. The
presence of adenomyotic tissue in the collected samples was
determined by two pathologists. All 24 patients (mean age,
39.9  5.6 years) with adenomyosis recruited for this study had
regular menstrual cycles, but none had received hormonal
treatment for at least 3 months before surgery. The experimental
procedures were approved by the institutional review boards of
Shiga University of Medical Science (Shiga, Japan), Takanohara
Central Hospital (Nara, Japan), Nagahama City Hospital (Shiga,
Japan), and Mochida Pharmaceutical Co., Ltd., and each patient
provided written consent to participate in this study.
Isolation and culture of ASCs
ASCs were puriﬁed from adenomyotic foci in myometrial tissue
and cultured as described previously [17] with slight modiﬁca-
tions. Brieﬂy, excised tissues were placed in phenol red-free
Dulbecco's minimum essential medium (DMEM)/F12 (HyClone
Laboratories, Inc., Logan, UT, USA) supplemented with 10% fetal
bovine serum (FBS) (HyClone Laboratories, Inc.) and antibiotic on
ice. Then, the tissues were minced in Hanks’ balanced salt solution
(HyClone Laboratories, Inc.) and digested with 0.5% collagenase
(Worthington Biochemical Corp., Freehold, NJ, USA) and 0.02%
DNase I (Worthington Biochemical Corp.) at 37 C for 2 h in a water
bath while shaking. The dispersed cells were ﬁltered through a 70-
mm nylon cell strainer to remove the undigested tissue pieces
containing glandular epithelium. For further separation from the
epithelial cell clumps by differential sedimentation, the cells were
resuspended in 2 mL culture medium and layered slowly over
10 mL medium in a centrifuge tube at 37 C in an atmosphere of 5%
CO2 for 30 min. After sedimentation, the top 8 mL of the medium
was collected. Finally, the medium containing stromal cells was
ﬁltered through a 40-mm nylon cell strainer. Final puriﬁcation was
achieved by allowing the stromal cells, which attach rapidly to a
60-mm culture dish (Nalge Nunc, Roskilde, Denmark), to adhere
selectively to the culture dishes for 30 min at 37 C in a 5% CO2
incubator, followed by removal of nonadherent epithelial cells.
When the ASCs reached conﬂuence, they were seeded into 92-mm
culture dishes (Nalge Nunc) at a density of 105 cells per dish with
phenol red-free DMEM/F12 medium supplemented with 10% FBS
and antibiotics, which were used for the following experiments.
We used ASCs in a monolayer culture after one passage.
Characterization of ASCs
Immunocytochemical staining for vimentin, cytokeratin, von
Willebrand factor (vWF), and a-smooth muscle actin were carried
out to conﬁrm characterization of isolated cells. Isolated ASCs were
seeded onto Lab-TekTM chamber slides (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) with DMEM supplemented with 10% FBS
containing antibiotics and then cultured for 48 h in a 5% CO2
incubator. The cells were ﬁxed with 4% formaldehyde at room
temperature for 1 h and permeabilized with 0.5% Triton X-100 in
PBS at room temperature for 5 min. Blocking was performed in PBS
containing 5% goat serum for 30 min at room temperature.
Subsequently, cells were washed three times for 5 min each using
PBS. These samples were incubated with the following primary
antibodies: monoclonal mouse anti-human vimentin (Dako Corp.,
Carpinteria, CA, USA; 1:100), cytokeratin (Dako Corp.; 1:100), vWF
(Dako Corp.; 1:50), and monoclonal rabbit anti-human a-smooth
muscle actin (Abcam, Cambridge, MA, USA; 1:500) for 1 h at room
temperature. The cells were washed three times for 5 min each
using PBS and then incubated with Alexa Fluor 488 goat anti-
mouse IgG (Invitrogen, Carlsbad, CA, USA; 1:500) or Alexa Fluor
488 goat anti-rabbit IgG (1:500) for 30 min at room temperature.
The samples were subsequently washed with PBS and mounted in
glycerol.
Analysis of the cell cycle with ﬂow cytometry
Cell cycle analysis was performed with ﬂow cytometry using a
ﬂuorescein isothiocyanate (FITC) 5-bromo-20-deoxyuridine (BrdU)
Flow Kit (BD Biosciences, San Jose, CA, USA) according to the
manufacturer’s instructions. Brieﬂy, the ASCs were plated at 105
cells/well in a 92-mm dish with phenol red-free DMEM/F12
medium containing 10% dextran-coated charcoal-treated fetal
bovine serum (DCC-FBS) (HyClone Laboratories, Inc.). The cells
were then serum starved by incubating in phenol red-free DMEM/
F12 medium containing 0.5% DCC-FBS for 24 h and then incubated
for 48 h in medium with either 108M of E2 alone (control cells) or
E2 and different concentrations of DNG (Mochida Pharmaceutical,
Tokyo, Japan) or P (Sigma), which were dissolved in dimethyl
sulfoxide (DMSO) at a ﬁnal concentration of 0.1% in all culture
media. E2 was added because adenomyosis develops in an
estrogen-dependent manner, and adenomyotic tissue contains
high levels of the estrogen synthetic enzyme, and thus, E2 is
probably highly produced in adenomyotic foci [2]. The cells were
labeled with 10 mg/mL BrdU for 2 h. After washing, the cells were
ﬁxed and permeabilized. Incorporated BrdU was exposed by DNase
treatment, and then cells were immunostained with FITC-labeled
anti-BrdU antibody. Total DNA was stained with 7-amino-
actinomycin D (7-AAD). Data were obtained using a ﬂow cytometer
(FACSCalibur; BD Biosciences) and analyzed with CellQuest Pro
software (BD Biosciences).
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Analysis of apoptotic cells with ﬂow cytometry
Apoptosis was analyzed with ﬂow cytometry using a FITC
Annexin V Apoptosis Detection Kit (BD Biosciences) according to
the manufacturer’s instructions. Brieﬂy, ASCs were plated at 105
cells/well in 92-mm dishes with phenol red-free DMEM/F12
medium containing 10% DCC-FBS. The media were replaced with
either 108M of E2 alone (control cells) or E2 plus different
concentrations of test compounds and incubated for 48 h at 37 C
in a 5% CO2 incubator. The cells were then harvested, washed twice
in PBS on ice, and resuspended in annexin V-binding buffer at a
concentration of 106 cells/mL. This suspension (100 mL) was
stained with 5 mL annexin V-FITC and 20 mL 7-AAD. The cells were
incubated for 15 min at room temperature. After adding 400 mL
binding buffer to each tube, the cells were analyzed with ﬂow
cytometry (FACSCalibur; BD Biosciences) using CellQuest Pro
software.
Measurement of caspase 3/7 activity
The cells were plated at 104 cells/well in a 96-well plate and
incubated for 4 h in phenol red-free DMEM/F12 medium contain-
ing 10% DCC-FBS with either 108M of E2 alone (control cells) or E2
plus different concentrations of P or DNG. After incubation, caspase
3/7 activity was measured using the Caspase-GloTM 3/7 assay
(Promega Corporation, Madison, WI, USA). Brieﬂy, the plates were
incubated at room temperature for 1 h, mixed with 100 mL
Caspase-GloTM 3/7 reagent at the end of the incubation period,
and luminescence intensity was determined using a microplate
reader (Inﬁnite M200; Tecan, Durham, NC, USA).
Statistical analysis
Data are expressed as the means  standard error of the mean
(SEM). The signiﬁcance of experiments to evaluate the effects of
drugs was examined using Steel’s test and the Mann–Whitney U
test. A probability (P) value <0.05 was considered statistically
signiﬁcant.
Results
Characterization of ASCs isolated from adenomyotic tissue
We conﬁrmed the characteristics of ASCs puriﬁed from
adenomyotic foci in myometrial tissue using immunocytochem-
istry. Fig. 1(A) shows a histological specimen of human
adenomyotic foci stained with hematoxylin and eosin. Fig. 1(B)
shows a phase-contrast image of ASCs. The morphology of
puriﬁed cells was spindle-shaped, similar to stromal cells, and
puriﬁed cells were positive for vimentin, a marker of stromal
cells, but negative for cytokeratin, vWF, and a-smooth muscle
actin, which are markers of epithelial, endothelial, and smooth
muscle cells, respectively (Fig. 1(C–F)). The purity of the ASC
population was >95%.
Fig. 1. Adenomyosis-derived cell cultures.
(A) Original adenomyosis tissue stained with hematoxylin and eosin (original magniﬁcation: 200). (B) Phase-contrast images of conﬂuent cultured cells. Cultured cells were
positive for vimentin (D), but not cytokeratin (C), a-smooth muscle actin (E), or von Willebrand factor (F). Cell nuclei in (B–F) were visualized with Hoechst 33,342. Scale bar,
100 mm.
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Effects of P and DNG on the cell cycle in ASCs
Relative to control conditions, P (108–106M) and DNG (108–
106M) signiﬁcantly increased the percentage of cells in the G0/G1
phase and signiﬁcantly decreased the percentage of cells in the S
phase (Table 1). However, we found no signiﬁcant difference in
cells in the G2/M phase at any concentration of either compound.
Effects of P and DNG on apoptosis in ASCs
To determine whether P and DNG could induce apoptosis in
ASCs, the translocation of phosphatidylserine from the inner to
outer layer of the plasma membrane in apoptotic cells was
examined using the FITC annexin V-binding assay (Table 2).
Relative to control conditions, P signiﬁcantly increased apoptosis
at concentrations of 108–107M. DNG also signiﬁcantly increased
apoptosis at all concentrations.
Effects of P and DNG on caspase 3/7 activity in ASCs
Compared to control conditions, cellular caspase 3/7 activity
was signiﬁcantly increased by both P (108–106M) and DNG
(108–106M) following incubation periods of 4 h (Table 2).
Comment
The present study revealed that the PR agonists, endogenous P
and the synthetic progestin DNG inhibited proliferation as
observed by a decrease in ASCs in the S phase. In addition, both
P and DNG increased annexin V-positive/7-ADD-negative ASCs and
caspase 3/7 activity, which are markers for apoptosis. These
ﬁndings indicated that progestational compounds inhibited cell
proliferation and induced apoptosis in human primary cultures of
ASCs. Induction of apoptosis by P has been reported in human
ovarian and endometrial cancer cell lines [18], and DNG induces
apoptosis in endometrial cells in a three-dimensional culture [19].
Norethisterone, a ﬁrst-generation progestin with androgenic
activity, induces apoptosis in endometriotic stromal cells from
ectopic endometrial tissue but P does not [20]. However, no reports
describing that progestational compounds induce apoptosis in
adenomyotic cells have been published. In this study, we
demonstrated for the ﬁrst time that progestational compounds,
P and DNG, induce apoptosis in adenomyotic cells.
Although recent studies have demonstrated that P and DNG
have antiproliferative effects on endometrial and endometriotic
cells through G0/G1 arrest [14,21], these reports did not demon-
strate induction of apoptosis. Our previous study indicated that the
pharmacological mechanism of G0/G1 arrest by P and DNG is
mediated by suppressing expression of the cell cycle regulator
cyclin D1 without inducing apoptosis or cytotoxicity in a human
endometrial epithelial cell line [13]. However, in this study, P and
DNG induced apoptosis in adenomyotic cells. The reason for the
difference in the response to progestational compounds between
endometrial epithelial cells and adenomyotic cells is unclear. P
decreases reactive oxygen species production and induces
apoptosis by increasing the expression of the proapoptotic genes
p53 and Bax and decreasing the expression of the antiapoptotic
gene Bcl-2 in ovarian and endometrial cancer cells through PRs
[18]. Moreover, in endometrial cells, P and DNG inhibit production
of prostaglandin E2 (PGE2), which inhibits the induction of
apoptosis [22], through PRs [12]. Adenomyosis exhibits higher
levels of oxidative DNA damage [23], expression of the PGE2
synthetic enzyme [24], and PRs [2]. Thus, induction of apoptosis by
endogenous P and DNG is likely mediated by inhibition of oxidative
stress through PRs in ASCs. However, the precise mechanisms by
which progestational compounds induce apoptosis remain to be
elucidated, and more research is needed.
DNG has good oral bioavailability and is highly selective for PRs
[25]. DNG was developed to treat endometriosis [25]. In our in vitro
study, DNG exerted direct effects on ASCs of inhibiting cell
proliferation and inducing apoptosis. It remains unclear whether
these direct effects of DNG on ASCs are also exerted in women with
adenomyosis. But these effects of DNG were exerted at 108mol/L
and higher. The concentration was low enough to exert the effects
of DNG in women because the reported blood DNG level was
around 107mol/L during treatment with a therapeutic dose for
endometriosis (1 mg DNG twice orally) [26]. Therefore, we assume
that these direct effects of DNG are also exerted in women. Some
rodent adenomyosis models have been reported [27], but no
appropriate in vivo model is available at the present time that
strictly reproduces the pathological features of adenomyosis in
women. Therefore, estimations of the clinical effects of DNG
observed through in vivo basic studies seem limited; clinical
studies are needed to ascertain the clinical effects of DNG. In
addition to the antiproliferative effects of DNG [13,14,16,19,21],
some in vitro studies have demonstrated that DNG directly inhibits
the expression of inﬂammatory cytokines, angiogenesis and nerve
growth factors, PGE2 synthetic enzymes, and aromatase
[11,12,15,28,29] in endometrial and endometriotic cells. These
factors are associated with the development and progression of
Table 1
Effects of progesterone (P) and dienogest (DNG) on the number of adenomyotic
stromal cells (ASCs) in the various phases of the cell cycle.
Drug Dose (mol/L) Cell cycle phase (% relative to control)
G0/G1 S G2/M
P 108 100.7  0.3a 76.1  5.2a 101.6  3.3
107 100.6  0.2a 73.6  4.2a 103.7  3.2
106 101.1  0.4a 68.6  3.5a 103.4  3.1
DNG 108 100.3  0.3 76.0  5.2a 106.2  5.8
107 100.8  0.3a 73.3  4.3a 101.6  2.8
106 100.8  0.2a 72.2  3.4a 101.1  2.5
Note: ASCs were serum starved in phenol red-free DMEM/F12 medium containing
0.5% dextran-coated charcoal-treated fetal bovine serum (DCC-FBS) for 24 h and
were then incubated for 48 h in phenol red-free DMEM/F12 medium containing 10%
DCC-FBS and 108M estradiol with or without (control) various concentrations of P
or DNG. The percentage of cells in each phase of the cell cycle (G0/G1, S, and G2/M)
compared with the control were determined with ﬂow cytometry. The effect of 0.1%
dimethyl sulfoxide as a vehicle control was assigned as 100%. Values are the
mean  SEM from 20 independent experiments using samples from different
women.
a P < 0.05 vs. control with Steel’s test.
Table 2
Effects of progesterone (P) and dienogest (DNG) on induction of apoptosis in
adenomyotic stromal cells (ASCs)
Drug Dose
(mol/L)
Apoptotic cellsb (% relative
to control)
Caspase 3/7 activity (% relative
to control)
P 108 114.5  5.8a 108.2  2.4a
107 116.8  12.0a 110.1  2.5a
106 113.5  4.2 106.8  1.9a
DNG 108 129.6  11.4a 112.0  3.0a
107 130.0  8.6a 113.3  3.1a
106 135.9  8.2a 115.2  2.4a
Note: ASCs were incubated in phenol red-free DMEM/F12 medium containing 10%
dextran-coated charcoal-treated fetal bovine serum and 108M estradiol with or
without (control) various concentration of P or DNG. The percentages of apoptotic
cells were determined after 48 h of treatment (n = 24), and caspase 3/7 activity was
determined after 4 h of treatment (n = 17); the effects of P and DNG were compared
with the control (0.1% dimethyl sulfoxide as the vehicle control, assigned as 100%).
Values are presented as the mean  SEM.
a P < 0.05 vs. control with Steel’s test.
b Annexin V-positive and 7-AAD-negative cells were detected with ﬂow
cytometry.
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adenomyosis. Taking into consideration the results of the present
study that used ASCs, along with and the results of the previous
studies, DNG is likely to be a useful option for the medical
treatment of adenomyosis. DNG seems to be safer and more easily
tolerated for long-term use, given its fewer side effects [25]. Once
the efﬁcacy of DNG for adenomyosis is conﬁrmed in other clinical
studies, it may be an ideal treatment.
In conclusion, both endogenous P and the synthetic progestin
DNG directly inhibit cellular proliferation and also induce
apoptosis in human ASCs. These pharmacological features of
progestational compounds provide insight into this therapeutic
strategy for treatment of adenomyosis.
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